Abstract
Abstract: :
Purpose:To evaluate efficacy of INTACS prescription inserts for the correction of myopia, three or more years after implantation. Methods:Prospective study of 188 eyes implanted with INTACS inserts and followed for 36 months (longer–term data will be available). Patients were selected for myopia of –1.00 D to –3.50 D. Outcome measures included change in UCVA, BCVA, MRSE, keratometry readings, pachymetry, visual symptoms and quality of vision, post–op complications and adverse outcomes. Results:UCVA was 20/40 or better in 97% of patients, with 89% seeing 20/25 or better, 79% seeing 20/20 or better, and 61% seeing 20/16 or better. There was an incremental improvement in UCVA for some patients over time, as 74% saw 20/20 or better at 12 months and 76% measured 20/20 or better at 24 months. BCVA was maintained by 56% of patients, while 23% gained one line or more, and 18% lost one line. No patient had induced cylinder greater than 1.00 D. Five patients or 2.6% had deep neovascularization. Conclusions:Results indicate that INTACS are effective in decreasing mild myopia, the correction is stable over time, results are predictable, and the device is safe and well–tolerated in the corneal stroma.
Keywords: visual acuity • contact lens • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials